Acrux Limited · ASX:ACR
Acrux — Investor Presentation (March 2005)
12 slides from Acrux's investor presentation, Mar 7, 2005
Slide 1: LL y
LL y oe ee Boe ees ee EEE ee SC i oo To y : LS 7) ain es ee Q Lo oy le 3 Q g We Le | a vo : oF ; a ay ‘i Co a. CL | : yy yy ; a 8 2 ; Vy ae i y ae / cn : ; oo a i ! ! | I ee DD ie De a WITH PRODUCTS IN LATE § : RLARGE GLOBAL 1 ARK a. i cn mn . ee oo i ee Lo cnc TTI ee oy EE TT TTT TT TT ee a iii nth
Slide 2: Lead product in final phase; next product will start phase 3 in 2005
a Lead product in final phase; next product will start phase 3 in 2005 Fewer, faster and lower cost trials because we use proven drugs Track record of commercial deals - Eli Lilly, Vivus, CSL More deal opportunities - 7 products in human clinical trials $29m cash reserves - sufficient to reach profi
Slide 3: Peer comparison of Australian pharma and drug delivery companies
“ACEUX 0.73 104 29.0 Eli Lilly, 3 1 0 Vivus, CSL Novogen 4.80 465 48.0 Few 1 3 0TC* psSivida 0,99 - 213 “22.0 Several, 1 0 Metabolic 0.83 192 11.2 3 1 0 “Pharmaxis 1.25 168 ™ 38.8 3 ™ 1 0 “Progen 3.90 140 ™ 14.4 3 ™ 3 0 Sirtex 41,99 110 15 Several, 0 1 Norwood ~- 0.50 : 83 8.20. Ferndale, Few Lin ‘0
Slide 4: Drug discovery versus drug delivery economics
Ih Drug Discovery 0.01% 15 Years Up to US$800 million Drug Delivery 10.0% 7 Years USS$15-50 million Acrux example - Evamist™ * Expected to launch in 2007 after 7 years of development * Acrux cost approx. US$9 million; VIVUS funding the final, simple trials
Slide 5: Formulation = proven drug + patented technology
Formulation = proven drug + patented technology v i ‘ + Proof of concept blood level study (“Phase 1”) MDTS® Commercial Deal Opportunity v FDA guidance on remaining trials v Phase 2 clinical trial Phase 3 clinical trial v Approval + Marketing
Slide 6: VIVUS and Eli Lilly (Elanco) commercial deals
HL * VIVUS: NASDAQ listed company focused on sexual function disorders — US. licence for Evamist™ and Testosterone MDTS® — Targeting billion dollar markets — US$13.3 million in milestones + sales royalties, US$2.3 million received ~— VIVUS funds R&D, manufacturing, sales and marketing — Acrux retain
Slide 7: Product pipeline: Evamist, testosterone, fentanyl and others
Evamist™ for 1.2 Vivus for USA Vivus in final US trials; file in 2006 for menopause US approval Testosterone for 1.0-4.0 Seeking rest of world partners Successful large Phase 2 trial; Vivus to female low libido start US Phase 3 in 2005 Fentanyl for severe 5.6 Out-license after Phas Trials successful
Slide 8: Goal is profit in FY ended June 2008
* Goal is profit in FY ended 30 June 2008, then rapid growth from multiple product royalties * Sufficient cash to achieve this and maintain a prudent buffer « FY 2005 loss will be higher than FY 2004; increased development spend to provide products as fast as possible for commercial deals to drive r
Slide 9: MDTS technology platform
MDTS® Applicator Used for simple, accurate & flexible dosing US Pat. appl.no. 10/442,323 & © ih UM TECHNOLOGY PLATEORS ent. achoss enlaces Haile Patchless Patch® Reservoir Forms an invisible reservoir within the skin US Pat. no. 6,818,226 ACROSS® Enhancers Allow drugs to pass through skin more rapid
Slide 10: Comparison of transdermal technologies
it Le : cin lait 1970 1990 No or low risk of skin irritation v x v Cosmetic acceptability x x v Dosage flexibility x x v Ease of manufacture x x v Cost effective v x v Range of applications x v v x x v Preference by patients
Slide 11: Key milestones and achievements
Comimercislisation deal for Feotanyl MODES “ompleted Began Phase | inical 2b clinical tri, fal for (Pha rone MDTS Nesiorone MDIS: for Evamist in U Key additional US Patent G IPO promised Milesiones Additional achievements
Slide 12: Lead product in final phase; next product will start phase 3 in 2005
a Lead product in final phase; next product will start phase 3 in 2005 Fewer, faster and lower cost trials because we use proven drugs Track record of commercial deals - Eli Lilly, Vivus, CSL More deal opportunities - 7 products in human clinical trials $29m cash reserves - sufficient to reach profi